ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

GRDX // GridAI Technologies Corp.

DES <GO> NASDAQ RQD COCKPIT → CIK 0001604191 ↗
Health Care • Biotechnology: Pharmaceutical Preparations
$5.45 ▼ -0.31 (-5.38%)
MKT CAP: $38.9M • VOL: 204.1K
GRDX // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE
PRIOR: RQD 26/100 [E] (+0 PT) • UNCHANGED
ROARABLE E
RQD CONFIDENCE
26 / 100 +0D
5 X 20-PT QUANT PILLARS
E 0 D 35 C 59 B 70 A 86+
Roarable Strong Sell — Forensic Risk / Avoid
01 MASSIVE / SEC XBRL
Forensic Fundamentals
6 / 20
CRITICAL
FCF +38.1% vs NI +64.6% • ROIC-WACC -28.6% • Z 3.2
02 INSTITUTIONAL TAPE & TREND
Whale & Options Flow
3 / 20
CRITICAL
52W RANGE 18% • VS 200D -6.7% • RSI 28.3
03 SEC XBRL CAPITAL ALLOCATION
Insider & Capital Conviction
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
04 FRED 90D r-MATRIX
Macro Regime Fit
6 / 20
CRITICAL
HEADWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00
05 10-K REDLINE AUDIT
Forensic 10-K Risk
[LOCKED] FLAGGED
UNLOCK BELOW TO REVEAL
ALERT

Why did GRDX's Insider & Capital Conviction & Forensic 10-K Risk sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever GRDX is Upgraded or Downgraded.

GRDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +117.13%▲ ASCENDING CHANNEL
2026-10-30O $5.33H $5.84L $4.70C $5.45VOL 147.1K
RES: $6.07SUP: $2.94SMA50: $4.00SMA200: $3.52
$7.27$5.88$4.49$3.10$1.71RES $6.07SUP $2.94$5.452026-04-302026-06-152026-07-312026-09-162026-10-30
GRDX // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE
UNDERWEIGHT CONVICTION: 29/100
BEAR 0
100 BULL

GridAI Technologies Corp. (GRDX) exhibits -30.0% gross margins and -20.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)
01. Operating Leverage & Capital Efficiency Moat

Sustained -30.0% gross profitability converts into -60.0% operating margin and -20.0% ROIC, outpacing sector cost of capital.

ROIC: -20.0% // GM: -30.0%
02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of — paired with -14.67% free cash flow yield supports self-funded R&D and capital return.

REV YOY: — // FCF YLD: -14.67%
03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 3.80 and Piotroski F-Score of 2/9 indicate low near-term refinancing stress.

ALTMAN Z: 3.80 // F-SCORE: 2/9
▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)
01. Multiple Compression & Duration Sensitivity

Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 24.0x // EV/EBITDA: —
02. Options Skew & Event Volatility Risk

Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $5.45 max pain.

IMPL MOVE: ±5.2% // P/C: 0.85
03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -60.0% net margins.

NET MARGIN: -60.0% // D/E: 0.45x
KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs — forward consensus, and institutional 13F positioning.
MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.10).
FORM 4 & 13F FLOW OPEN OWN <GO>
FILER SIDE $ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>
UNUSUAL OPTIONS TAPE OPEN OPT <GO>
STRIKE / EXP TYPE PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>
KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>
TRAILING P/E —
FORWARD P/E —
EV / EBITDA —
FCF YIELD -14.67%
GROSS MARGIN -30.0%
OPERATING MARGIN -60.0%
NET MARGIN -60.0%
ROIC % -20.0%
REV GROWTH YOY —
DILUTED EPS TTM —
DEBT / EQUITY —
DIVIDEND YIELD 0.00%
RSI-14 MOMENTUM 54.5
5Y EQUITY BETA —
FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>
MACRO CORRELATION CALIBRATION ACTIVE BELOW.
FRED MACRO REGIME STRESS-TEST SIMULATOR // GRDXPEARSON R VARIANCE ENGINE
01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO
02 // POSITION NOTIONAL EXPOSURE
HEADLINE STRESS SCORE
75/100SEVERE DRAWDOWN PRESSURE
PRIMARY FACTOR EXPOSURE
DFII10 // -0.61 r
Latest: 2.08%
EST. DIRECTIONAL MOVE
-8.50%
Implied Px: $4.99
EST. DOLLAR VARIANCE
-$4,248
On $50,000 Notional
[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for GRDX & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>